At Genece, we’re eager to succeed in our mission and strive to create an environment that enables our team.
We benefit from the nimbleness of a small company with just enough structure to enable quality and efficiency. We believe this balance is key to our Company’s and our team members’ long-term success.
Our close-knit team prioritizes mindfulness and embraces challenges together—creating an environment of trust and true camaraderie that supports our collective and personal goals.
We’re looking for people ready to change the trajectory of cancer. If you have experience in early cancer detection, ML/AI for clinical diagnostics, or CLIA-certified WGS lab testing, send us your resume at people@genecehealth.com and let us know how you can help make an impact.
Who we are
Genece (pronounced GEN-iss) is a brand new, unique oncology testing services startup with proprietary technology and significant funding from GC Biopharma in South Korea. Over the last five years, GC has developed a combination of next-generation sequencing, patented algorithms, SNV detection, fragment analysis and other techniques to perform early-stage screening for various cancers. GC is the largest life-sciences company in Korea.
We are transferring these technologies to Genece, collaborating with GC on productizing these technologies and working independently to invent and develop additional, complementary products for the U.S. market. We work closely with colleagues in Korea who provide significant expertise and resources. We leverage patented mathematical methods and algorithmic enhancements to analyze NGS data. Their approach has demonstrated high performance at a much lower cost versus competitive alternatives. The vision is to build a second-to-none cancer screening services company by leveraging GC technology in the near term in combination with in-house technology invention and IP development longer term.
Job summary
We are seeking a highly skilled and motivated Data Scientist with experience in Next Generation Sequencing (NGS) and genomics data analysis to join our early-stage cancer screening team. The ideal candidate will be responsible for analyzing and interpreting complex multimodal genomic and clinical data sets, identifying patterns, and providing insights to support the development and maintenance of a computational diagnostic platform.
Your responsibilities will be to:
Your ideal qualifications
If you are a data-driven problem solver who is passionate about using cutting-edge technologies to advance early cancer research, we encourage you to apply for this exciting opportunity at:
Who we are
Genece (pronounced GEN-iss) is a brand new, unique oncology testing services startup with proprietary technology and significant funding from GC Biopharma in South Korea. Over the last five years, GC Biopharma has developed a combination of next-generation sequencing, patented algorithms, SNV detection, fragment analysis and other techniques to perform early-stage screening for various cancers. We will transfer these technologies to Genece, collaborate with GC Biopharma on productizing these technologies and work independently to invent and develop additional, complementary products for the U.S. market. We work closely with colleagues in Korea, who provide significant expertise and resources. We leverage patented mathematical methods and algorithmic enhancements to analyze NGS data. Their approach has demonstrated high performance at a much lower cost versus competitive alternatives. The vision is to build a second-to-none cancer screening services company by leveraging GC Biopharma technology in the near term in combination with in-house technology invention and IP development longer term.
Job summary
We are looking for a motivated Research Associate. The successful candidate will contribute to technology transfer and product improvement of NGS-based liquid biopsy tests for oncology applications. This position will plan, execute, analyze, and document research, development and verification and validation (V&V) studies. They will have experience doing similar functions under design control, for an LDT, per CAP/CLIA standards. The ideal candidate will be an enthusiastic, flexible team member who learns quickly, is detail oriented and thrives in a fast-paced environment.
What you will be responsible for
Your ideal qualifications
Who we are
Genece (pronounced GEN-iss) is a brand new, unique oncology testing services startup with proprietary technology and significant funding from GC Biopharma in South Korea. Over the last five years, GC Biopharma has developed a combination of next-generation sequencing, patented algorithms, SNV detection, fragment analysis and other techniques to perform early-stage screening for various cancers. We will transfer these technologies to Genece, collaborate with GC Biopharma on productizing these technologies and work independently to invent and develop additional, complementary products for the U.S. market. We work closely with colleagues in Korea, who provide significant expertise and resources. We leverage patented mathematical methods and algorithmic enhancements to analyze NGS data. Their approach has demonstrated high performance at a much lower cost versus competitive alternatives. The vision is to build a second-to-none cancer screening services company by leveraging GC Biopharma technology in the near term in combination with in-house technology invention and IP development longer term.
Job summary
We are looking for a motivated Scientist. The successful candidate will contribute to technology transfer and product improvement of NGS-based liquid biopsy tests for oncology applications. This position will plan, execute, analyze, and document research, development and verification and validation (V&V) studies. They will have experience doing similar functions under design control, for an LDT, per CAP/CLIA standards. The ideal candidate will be an enthusiastic, flexible team member who learns quickly, is detail oriented and thrives in a fast-paced environment.
What you will be responsible for
Your ideal qualifications
Our services help physicians get the answers needed to detect cancer earlier—improving both patient outcomes and access.
About Us